According to a new
report published by Transparency Market Research “Meningococcal
Vaccines Market - Global Industry Analysis, Size, Share, Growth,
Trends and Forecast 2014 - 2022,” the meningococcal vaccines market
was valued at USD 1.5 billion in 2013 and is expected to reach a
value of USD 4.4 billion in 2022, growing at a CAGR of 12.4% from
2014 to 2022.
Browse the full
Meningococcal Vaccines Market Report at
http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html
Meningococcal
disease is caused by the bacterium Neisseria meningitidis and occurs
sporadically throughout the world with seasonal variations. It
accounts for a proportion of endemic bacterial meningitis, which can
progress very rapidly leading to death within 24 hours from the onset
of symptoms. The disease is often misinterpreted as common flu in
most of the cases. Five out of the several serogroups are known to
cause meningococcal disease. The serogroups responsible for causing
the disease comprise A, B, C, Y and W-135. The causative agent N.
meningitidis is commonly found in the nasopharynx of humans and gets
transmitted through droplet inhalation by means of close contact such
as exposure to smokers, crowded living conditions such as
dormitories, certain inherited disorders of the immune system,
functional/anatomical asplenia or through intimate oral contact among
others. According to the European Federation of Pharmaceutical
Industries and Association, every year, meningitis affects almost
500,000 people globally, primarily affecting toddlers, infants and
young adults, due to weaker immune system.
The global market
for meningococcal vaccines is segmented broadly into vaccine types
namely, polysaccharide, conjugate, combination and Men B vaccines.
The report also provides analysis for vaccine under development,
NmVac4-DT by JN- International that is expected to be commercialized
during the forecast period 2014 to 2022. The vaccine types are
further segmented by different brands available in the market. The
conjugate vaccines segment is likely to lead the overall
meningococcal vaccines market in terms of revenue, which is estimated
to be worth USD 2,655.0 million by 2022 at a CAGR of 8.9%. According
to Department of Health, U.K., Bexsero is the first serogroup B
vaccine to be incorporated into the national immunization program and
is expected to be available in the market for sales post settle of
price negotiations. The U.S. FDA recently approved two Men B
vaccines: Trumenba by Pfizer in October 2014 and Bexsero by Novartis
in January 2015.
Browse the full
Press release Report :
The market for
meningococcal vaccines is largely driven by increasing government
intervention in reforming the healthcare infrastructure and
incorporation of legislations specific to meningococcal vaccination.
The public-private partnerships for conducting research and
development, and manufacturing of quality vaccines at an affordable
price are also contributing positively in driving market growth.
Awareness campaigning from government and non-profit organizations,
and obligatory immunization for individuals heading to Mecca (for
Hajj pilgrimage) and the South African meningitis belt will also
contribute to growth of this market. High cost of few but vital
vaccines, such as Bexsero, and need for efficient cold chain
logistics to maintain safety and efficacy of the vaccine are expected
to be some of the major factors posing a challenge to the adequate
uptake of these vaccines.
meningococcal-vaccines-market
The key players
dominating the global meningococcal vaccines market include Sanofi
Pasteur (the vaccine division of Sanofi SA), Novartis International
AG and GSK plc. These players account for more than 90% of the
meningococcal vaccines market. Players such as Serum Institute of
India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd.,
Nuron Biotech and Baxter account for the remaining market share.
The global
meningococcal vaccines market is segmented as follow:
Meningococcal
Vaccines Market, by Type
Polysaccharide
Vaccines, by Brand
Menomune
Mencevax
NmVac4
Others
Quadri Meningo
Bi Meningo
Conjugate Vaccines,
by Brand
Menactra
Menveo
NeisVac-C
Nimenrix
Meningitec
Menjugate
MenAfriVac
Combination
Vaccines, by Brand
MenHibrix
Menitorix
NmVac4-DT
Men B Vaccines, by
Brand
Bexsero
Trumenba
Meningococcal
Vaccines Market, by Geography
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia Pacific
Japan
Australia
Rest of Asia Pacific
Rest of the World
Latin America
Africa
Rest of RoW
Request a Brochure
of this Report :
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1666
About Us
Transparency Market
Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. Our experienced team of
Analysts, Researchers, and Consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our data repository
is continuously updated and revised by a team of research experts, so
that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in
developing distinctive data sets and research material for business
reports.
Contact
Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
